Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events
ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
Panelists discuss how distinguishing between limited-stage and extensive-stage small cell lung cancer is essential for guiding treatment strategies, accurately staging disease, and setting appropriate expectations for prognosis and therapeutic outcomes.
.png?width=580&upscale=true&name=marketing%20image%20(10).png)